drugset
drugset / Trial / NCT05229497

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

NCT05229497 ↗

Phase 1/2 Active not recruiting 154 enrolled Akeso
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors

Timeline

Start
2022-05-04
Primary completion
2026-12-31
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject AK117 Monoclonal antibody 30 mg/kg Intravenous
Subject AK117 Monoclonal antibody 45 mg/kg Intravenous
Subject Ivonescimab Monoclonal antibody 10 mg/kg Intravenous
Subject Ivonescimab Monoclonal antibody 20 mg/kg Intravenous
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified 80 mg/m2 Intravenous
Background Cisplatin Other / unclassified 100 mg/m2 Intravenous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background fluorouracil Small molecule — Intravenous

Indications

cancer